UK CDMO Aesica unveils a new £30m high capacity manufacturing facility

19 September 2013

UK contract development and manufacturing organization (CDMO) Aesica Pharmaceuticals has announced the creation of a new High Capacity Manufacturing Facility following a £30 million ($47.6 million) investment at its Queenborough, Kent, site, for the production of a solid dose medication used in treating one of the world’s most common lifestyle diseases: type 2 diabetes in adults. The actual compound was not identified.

Following the official opening on September 19, commercial production at the facility will commence in November. The facility contains a large amount of highly technical and specialist equipment including spray granulators, coaters, tablet presses, a delumper, blender and a sieve system, the company noted.

Aesica says it is well established as a manufacturer and a major exporter of formulated products with this latest investment reflecting the continued growth in export demand experienced by the company. This specific product manufactured at the new facility has global sales and is set for worldwide export.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK